ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate | 1332486-09-5

分子结构分类

有机化合物 - 有机杂环化合物 - 喹啉及其衍生物

中文名称

——

中文别名

——

英文名称

ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate

英文别名

Ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate；ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-6,8-dihydroquinoline-3-carboxylate

ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate化学式

CAS

1332486-09-5

化学式

C₁₄H₁₅Cl₂NO₃

mdl

——

分子量

316.184

InChiKey

SSESXHWTLKMVTK-UHFFFAOYSA-N

BEILSTEIN

——

EINECS

——

计算性质

辛醇/水分配系数(LogP)：

3.6
重原子数：

20
可旋转键数：

3
环数：

2.0
sp3杂化的碳原子比例：

0.5
拓扑面积：

56.3
氢给体数：

0
氢受体数：

4

上下游信息

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]5′-oxide	1332490-87-5	C₃₃H₄₆F₃NO₃Si	589.814
——	(3′S,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(5-(trifluoromethyl)pyridin-2-yl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332489-07-2	C₃₂H₄₅F₃N₂O₂Si	574.802
——	(3R,9S)-9-((tert-butyldimethylsilyl)oxy)-4-isopropyl-7,7-dimethyl-3-(4-(trifluoromethyl)phenyl)-2',3',5',6,6',7,8,9-octahydro-3H-spiro[furo[3,4-c]quinoline-1,4'-pyran]	1332489-18-5	C₃₃H₄₆F₃NO₃Si	589.814
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(6-(trifluoromethyl)pyridin-3-yl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-98-8	C₃₂H₄₅F₃N₂O₂Si	574.802
——	2-(4-((3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]-3′-yl)phenyl)-2-methylpropanenitrile	1332489-08-3	C₃₆H₅₂N₂O₂Si	572.907
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-7′,7′-dimethyl-4′-(tetrahydro-2H-pyran-4-yl)-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-91-1	C₃₅H₄₈F₃NO₃Si	615.852
——	4-((3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]-3′-yl)benzonitrile	1332489-06-1	C₃₃H₄₆N₂O₂Si	530.826
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-ethyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332489-25-4	C₃₂H₄₄F₃NO₂Si	559.788
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-3′-(4-fluorophenyl)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-94-4	C₃₂H₄₆FNO₂Si	523.807
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethoxy)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332489-03-8	C₃₃H₄₆F₃NO₃Si	589.814
——	(3′S,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(5-(trifluoromethyl)pyridin-2-yl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332485-09-2	C₂₆H₃₁F₃N₂O₂	460.54
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isoprorpyl-,7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-86-4	C₃₃H₄₆F₃NO₂Si	573.814
——	(3′S,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-,7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332484-89-5	C₃₃H₄₆F₃NO₂Si	573.814
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-3′-(4-tert-butylphenyl)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-97-7	C₃₆H₅₅NO₂Si	561.924
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-cyclopentyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332488-92-2	C₃₅H₄₈F₃NO₂Si	599.852
——	(S)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(5-(trifluoromethyl)pyridin-2-yl)methanol	1332488-69-3	C₃₂H₄₅F₃N₂O₂Si	574.802
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-7,7-dimethyl-2-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332487-52-1	C₃₅H₄₈F₃NO₃Si	615.852
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(3-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]	1332489-31-2	C₃₃H₄₆F₃NO₂Si	573.814
——	(3′R,9′S)-9′-(tert-butyldimethylsilyloxy)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclohexane-1,1′-furo[3,4-c]quinoline]	1332488-89-7	C₃₄H₄₈F₃NO₂Si	587.841
——	(3R,9S)-9-(tert-butyldimethylsilyloxy)-4-isopropyl-1,1,7,7-tetramethyl-3-(4-(trifluoromethyl)phenyl)-1,3,6,7,8,9-hexahydrofuro[3,4-c]quinoline	1332488-88-6	C₃₁H₄₄F₃NO₂Si	547.777
——	(3R,9S)-4-isopropyl-7,7-dimethyl-3-(4-(trifluoromethyl)phenyl)-2’,3’,5’,6,6’,7,8,9-octahydro-3H-spiro[furo[3,4-c]quinoline-1,4’-pyran]-9-ol	1332485-18-3	C₂₇H₃₂F₃NO₃	475.551
——	(3S,9R)-4-isopropyl-7,7-dimethyl-3-(4-(trifluoromethyl)phenyl)-2',3',5′,6,6′,7,8,9-octahydro-3H-spiro[furo[3,4-c]quinoline-1,4'-pyran]-9-ol	——	C₂₇H₃₂F₃NO₃	475.551
——	(3′R,9′S)-4′-ethyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332485-25-2	C₂₆H₃₀F₃NO₂	445.525
——	(3′R,9′S)-3′-(4-fluorophenyl)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-96-4	C₂₆H₃₂FNO₂	409.544
——	(3′R,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethoxy)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332485-05-8	C₂₇H₃₂F₃NO₃	475.551
——	2-(4-((3′R,9′S)-9′-hydroxy-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]-3′-yl)phenyl)-2-methylpropanenitrile	1332485-10-5	C₃₀H₃₈N₂O₂	458.644
——	(3′R,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(6-(trifluoromethyl)pyridin-3-yl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332485-00-3	C₂₆H₃₁F₃N₂O₂	460.54
——	2-(4-((R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(hydroxy)methyl)phenyl)-2-methylpropanenitrile	1332487-12-3	C₃₆H₅₂N₂O₂Si	572.907
——	(3′R,9′S)-7′,7′-dimethyl-4′-(tetrahydro-2H-pyran-4-yl)-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-93-1	C₂₉H₃₄F₃NO₃	501.589
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332487-90-7	C₃₂H₄₄F₃NO₂Si	559.788
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol	1332488-57-9	C₃₂H₄₅F₃N₂O₂Si	574.802
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-fluorophenyl)methanol	1332487-55-4	C₃₂H₄₆FNO₂Si	523.807
——	4-((3′R,9′S)-9′-hydroxy-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]-3′-yl)benzonitrile	1332485-08-1	C₂₇H₃₂N₂O₂	416.563
——	(3′R,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclohexane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-92-0	C₂₈H₃₄F₃NO₂	473.579
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclohexenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332489-97-0	C₃₄H₄₈F₃NO₂Si	587.841
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(3-(trifluoromethyl)phenyl)methanol	1332487-97-4	C₃₃H₄₆F₃NO₂Si	573.814
——	(3′R,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-87-3	C₂₇H₃₂F₃NO₂	459.552
——	(3′S,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-88-4	C₂₇H₃₂F₃NO₂	459.552
——	4-((R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(hydroxy)methyl)benzonitrile	1332487-69-0	C₃₃H₄₆N₂O₂Si	530.826
——	(3′R,9′S)-3′-(4-tert-butylphenyl)-4′-isopropyl-7′,7′-dimethyl-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-99-7	C₃₀H₄₁NO₂	447.661
——	(3′R,9′S)-4′-cyclopentyl-7′,7′-dimethyl-3′-(4-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332484-94-2	C₂₉H₃₄F₃NO₂	485.59
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332487-50-9	C₃₃H₄₆F₃NO₂Si	573.814
——	(S)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332487-51-0	C₃₃H₄₆F₃NO₂Si	573.814
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-(3,6-dihydro-2H-pyran-4-yl)-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332487-79-2	C₃₃H₄₆F₃NO₃Si	589.814
——	(3′R,9′S)-4′-isopropyl-7′,7′-dimethyl-3′-(3-(trifluoromethyl)phenyl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinolin]-9′-ol	1332485-29-6	C₂₇H₃₂F₃NO₂	459.552
——	(3′R,9′S)-7′,7′-dimethyl-3′-phenyl-4′-(propan-2-yl)-6′,7′,8′,9′-tetrahydro-3′H-spiro[cyclopentane-1,1′-furo[3,4-c]quinoline]-9′-ol	——	C₂₆H₃₃NO₂	391.554
——	(3R,9S)-4-isopropyl-1,1,7,7-tetramethyl-3-(4-(trifluoromethyl)phenyl)-1,3,6,7,8,9-hexahydrofuro[3,4-c]quinolin-9-ol	1332484-91-9	C₂₅H₃₀F₃NO₂	433.514
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethoxy)phenyl)methanol	1332487-67-8	C₃₃H₄₆F₃NO₃Si	589.814
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-4-cyclopentenyl-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-tert-butylphenyl)methanol	1332487-61-2	C₃₆H₅₅NO₂Si	561.924
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-2-isopropyl-7,7-dimethyl-4-(prop-1-en-2-yl)-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	1332488-42-2	C₃₁H₄₄F₃NO₂Si	547.777
——	(R)-((S)-5-(tert-butyldimethylsilyloxy)-2-isopropyl-7,7-dimethyl-4-(prop-1-en-2-yl)-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol	——	C₃₁H₄₄F₃NO₂Si	547.777

反应信息

作为反应物：

描述：

ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate 在 2,6-二甲基吡啶、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、硼烷-N,N-二乙基苯胺、 (1R,2S)-1-氨基-2-茚醇、二异丁基氢化铝、戴斯-马丁氧化剂、乙酰氯、 sodium iodide 作用下，以四氢呋喃、二氯甲烷、甲苯、乙腈为溶剂，反应 69.0h，生成 (S)-5-(tert-butyldimethylsilyloxy)-4-iodo-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinoline-3-carbaldehyde

参考文献：

名称：

Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation

摘要：

本发明涉及由式I定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理活性。特别地，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防受该酶抑制影响的疾病。

公开号：

US20130053404A1
作为产物：

描述：

3-氨基-5,5-二甲基-2-环己烯-1-酮在 N,N-二甲基甲酰胺三氯氧磷作用下，反应 12.17h，生成 ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate

参考文献：

名称：

[EN] TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION
[FR] DÉRIVÉS DE PYRIDINE TRICYCLIQUE, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS, LEUR UTILISATION ET L'UN DE LEURS PROCÉDÉS DE SYNTHÈSE

摘要：

本发明涉及由式（I）定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理活性。特别地，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防受该酶抑制影响的疾病。

公开号：

WO2012110599A1

点击查看最新优质反应信息

文献信息

TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION

申请人：WAGNER Holger

公开号：US20120046304A1

公开（公告）日：2012-02-23

The present invention relates to compounds defined by formula I wherein the variables R 1 -R 8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

本发明涉及由公式I定义的化合物其中变量R1-R8定义如说明书中所述，具有宝贵的药理活性。特别是，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适合用于治疗和预防可以通过抑制该酶而影响的疾病。
Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation

申请人：Wagner Holger

公开号：US20130053404A1

公开（公告）日：2013-02-28

The present invention relates to compounds defined by formula I wherein the variables R 1 -R 8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

本发明涉及由式I定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理活性。特别地，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防受该酶抑制影响的疾病。
[EN] TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION<br/>[FR] DÉRIVÉS DE PYRIDINE TRICYCLIQUE, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS, LEUR UTILISATION ET L'UN DE LEURS PROCÉDÉS DE SYNTHÈSE

申请人：BOEHRINGER INGELHEIM INT

公开号：WO2012110599A1

公开（公告）日：2012-08-23

The present invention relates to compounds defined by formula (I), wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

本发明涉及由式（I）定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理活性。特别地，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防受该酶抑制影响的疾病。
[EN] TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION<br/>[FR] DÉRIVÉS TRICYCLIQUES DE PYRIDINE, MÉDICAMENTS CONTENANT LESDITS COMPOSÉS, UTILISATION ASSOCIÉE ET PROCÉDÉ DE PRÉPARATION ASSOCIÉE

申请人：BOEHRINGER INGELHEIM INT

公开号：WO2011101424A1

公开（公告）日：2011-08-25

The present invention relates to compounds defined by formula (I) wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

本发明涉及由式（I）定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理活性。特别是，这些化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防受该酶抑制影响的疾病。
US9029544B2

申请人：——

公开号：US9029544B2

公开（公告）日：2015-05-12

ethyl 2,4-dichloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carboxylate | 1332486-09-5

分子结构分类

计算性质

上下游信息

反应信息

文献信息

同类化合物

相关结构分类

热门分子